Dr Lal PathLabs shares jump 8% to 52-week high after Nomura raises target on Q1 beat
Shares of Dr Lal PathLabs rose as much as 7.7% on Monday, July 27, to a 52-week high, after brokerage firm Nomura raised its target price on the diagnostics company following a stronger-than-expected June-quarter performance. Nomura reiterated its “Buy” rating on the stock and increased its price target to ₹2,085 from ₹2,000, implying an upside…
